Klivira
Request demo

Optimizing Urology AIM Specialty Health Integration for Prior Authorization

Achieving seamless **urology AIM Specialty Health integration** is critical for managing the complex prior authorization landscape in contemporary urological care.

Urology practices frequently encounter specialty benefit managers (SBMs) like AIM Specialty Health for high-cost imaging, procedures, and certain specialty drugs. Navigating their specific review criteria and submission portals adds significant administrative burden, impacting patient access and revenue cycles. Klivira provides the automation layer to streamline these interactions.

The Role of Specialty Benefit Managers in Urology Prior Authorization

Urology practices manage a diverse range of services, from BPH treatments like UroLift and Aquablation to advanced prostate cancer therapeutics such as Pluvicto and Xtandi, and complex imaging like multiparametric prostate MRI and PSMA PET. Specialty benefit managers, including AIM Specialty Health, often oversee utilization review for these high-cost services, introducing an additional layer of PA complexity and specific documentation demands.

Key Urology Services Often Subject to Specialty Benefit Manager Review

  • Advanced imaging: Multiparametric prostate MRI, PSMA PET imaging (Gallium-68 PSMA, Pylarify)
  • Minimally invasive BPH procedures: UroLift, Rezum, Aquablation
  • Robotic urologic surgery: Prostatectomy, partial/radical nephrectomy, cystectomy
  • Select high-cost specialty drugs: Oral androgen-receptor inhibitors (Xtandi, Zytiga), PSMA-targeted radiopharmaceuticals (Pluvicto)
  • Neuromodulation: Sacral neuromodulation (InterStim) for OAB

Navigating AIM Specialty Health's Specific Documentation for Urology

As a specialty benefit manager, AIM Specialty Health often requires granular clinical documentation beyond standard medical necessity for services like advanced imaging or complex procedures. Urology teams must meticulously gather evidence, referencing AUA Clinical Practice Guidelines and NCCN for urologic oncology, to meet these payer-specific requirements and avoid common denials related to insufficient conservative therapy duration or staging documentation.

Essential Clinical Data for Urology PA Submissions

  • For prostate cancer treatments: Gleason score, stage, PSA levels, prior treatments, NCCN-compendium-supported indication.
  • For BPH treatments (e.g., UroLift, Rezum, Aquablation): Symptom score (IPSS), prostate size, documented failed medical therapy trial duration.
  • For PSMA imaging: Biochemical recurrence documentation (PSA rise post-treatment) or initial staging indication per NCCN guidelines.
  • For neuromodulation (InterStim): Documentation of failed conservative therapy and trial-phase results.
  • For erectile dysfunction treatments: Documentation of prior PDE5 inhibitor trials, where applicable by plan type.

Klivira's Integrated Solution for Urology Prior Authorization with AIM

Klivira automates the prior authorization submission process for urology, directly integrating with EMRs to extract necessary clinical data and connect with specialty benefit managers like AIM Specialty Health. Our platform applies AUA/NCCN-guideline-aware policy logic, tracks prostate cancer regimens, and streamlines documentation for BPH conservative-therapy trials and advanced imaging, reducing manual effort and accelerating approval times for critical urological care.

Frequently asked questions

What urology services commonly require PA through specialty benefit managers like AIM Specialty Health?

High-cost services such as advanced imaging (e.g., multiparametric prostate MRI, PSMA PET), minimally invasive BPH procedures (UroLift, Aquablation), robotic urologic surgeries, and certain specialty drugs for prostate cancer are frequently subject to review by specialty benefit managers, including AIM Specialty Health.

How does Klivira handle specific documentation for prostate cancer treatments?

Klivira's platform extracts key data points like Gleason score, PSA, stage, and prior treatments directly from the EMR. It then applies NCCN-guideline-aware logic to ensure all required information is present and correctly formatted for submission to specialty benefit managers, supporting timely approval for critical oncology care.

Can Klivira help with PA for BPH procedures like UroLift or Aquablation?

Yes, Klivira automates PA for BPH procedures by streamlining the collection of required documentation, such as IPSS scores, prostate size, and evidence of failed medical therapy trials. This ensures submissions meet the specific criteria of specialty benefit managers, including AIM Specialty Health, reducing administrative burden.

What are common denial reasons for urology PAs submitted to specialty benefit managers?

Common denial reasons include insufficient documentation of conservative therapy duration for BPH or OAB, medical-necessity gaps for advanced prostate cancer drugs without proper staging, and NCD/LCD constraints for specific imaging. Klivira's system helps pre-validate submissions against known requirements to mitigate these issues.

Does Klivira integrate with my EMR for urology PA submissions?

Klivira offers robust EMR integration capabilities, allowing for automated extraction of clinical data directly from your system. This reduces manual data entry, improves accuracy, and accelerates the prior authorization workflow for all urology services requiring review by specialty benefit managers like AIM Specialty Health.

Related coverage

Other urology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo